Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
Efficacy and safety of Taspoglutide monotherapy in drug-naive Type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled Phase 3 study (T-emerge 1).